Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT04555434

Effects of Probiotics (P. Pentosaceus, L. Lactis or L. Helveticus) in NASH

Effects of Probiotics (P. Pentosaceus, L. Lactis or L. Helveticus) in Patients With Nonalcoholic Hepatitis

Sponsor: Chong Kun Dang Pharmaceutical

Conditions MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease Non-Alcoholic Fatty Liver Disease

Interventions Probiotics

Updated 7 times since 2020 Last updated: Feb 17, 2026 Started: Sep 20, 2020 Primary completion: Sep 11, 2022 Completion: Dec 1, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease and Non-Alcoholic Fatty Liver Disease and is currently completed. Chong Kun Dang Pharmaceutical leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE1/PHASE2

Status: Unknown → Completed · Phase: NA → PHASE1/PHASE2
Sep 2025 — Feb 2026 [monthly]

Unknown NA
Sep 2024 — Sep 2025 [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Oct 2022 — Jul 2024 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status

▶ Show 2 earlier versions

Jan 2021 — Oct 2022 [monthly]

Recruiting NA
Oct 2020 — Jan 2021 [monthly]

Recruiting NA

First recorded

Sep 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chong Kun Dang Pharmaceutical
Chuncheon Sacred Heart Hospital

Data source: Chuncheon Sacred Heart Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chuncheon, South Korea